Select a community
All Communities
Home > Community Treatment Reports > Emsam (selegiline) Treatment Report
What is Emsam?

Emsam® is a brand name for the transdermal delivery formulation of selegiline, an Monoamine Oxidase Inhibitor (MAO) antidepressant. It is used to treat majore depressive disorder.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Treat my mood condition(s) 9 2
Depression 7 5
Anxiety 1 1

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
1 14%
Moderate
1 14%
Mild
3 43%
None
2 29%

Most commonly reported side effects

Dietary restrictions
3 43%
Jittery feeling
1 14%
Loss of appetite
1 14%
Insomnia
1 14%
  • Mild
  • Moderate
  • Severe

Dosages

  6 mg/24 hr daily 9 mg/24 hr daily 12 mg/24 hr daily 12 mg daily
  2 Number of Patients: 2 4 Number of Patients: 4 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Emsam (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work
7 70% Did not seem to work: 70%
Expense
3 30% Expense: 30%
Side effects too severe
3 30% Side effects too severe: 30%
Doctor's advice
2 20% Doctor's advice: 20%
Personal research
1 10% Personal research: 10%
Other
1 10% Other: 10%

See all 10 patients who’ve stopped taking Emsam

Duration See details about how long patients take this treatment ▼

Currently Taking Emsam

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
3
2
1
0

Stopped Taking Emsam

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
3
3
1
2
1
0

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
7 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
1 14%
Somewhat
1 14%
A little
3 43%
Not at all
2 29%

Cost

Paid out of pocket

$200+
1 14%
$100-199
1 14%
$50-99
0 0%
$25-49
3 43%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 23, 2009.